Treatment of cystic fibrosis and other rare lung diseases / Arata Azuma, Michael S. Schechter, editors.
Contributor(s): Azuma, Arata,, editor literario | Schechter, Michael S.,, editor literario
Material type:
E-bookSeries: (Milestones in drug therapy, 2296-6056).Publisher: Switzerland : Springer, 2017Description: 1 recurso en línea.ISBN: 3034809778; 9783034809771.Subject: Fibrosis quística
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RC858.C95 T743 2017 EB (Browse shelf(Opens below)) | Acceso electrónico | eBook.20022910 |
SpringerLink Springer Biomedical and Life Sciences eBooks 2017 English+International
Incluye referencias bibliográficas
Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
There are no comments on this title.